Search
pegademase bovine (Adagen)
Indications:
- enzyme replacement therapy for patients with severe combined immunodeficiency disease (SCID) due to adenosine deaminase (ADA) deficiency
Dosage:
- dosage individualized based on monitoring of plasma ADA activity
- weekly IM administration
Injection: 250 units/mL
Pharmacokinetics:
- peak plasma levels of ADA activity reached 2-3 days following IM administration
- plasma elimination half-life of ADA following IM administration of Adagen is 3 to > 6 days
Mechanism of action:
- (monomethoxypolyethylene glycol succinimidyl) 11-17- adenosine deaminase
- conjugate of numerous strands of monomethoxypolyethylene glycol covalently attached to the enzyme adenosine deaminase
General
metabolic agent (metabolic modifier)
References
- Adagen (pegademase bovine) injection
http://www.adageninfo.com/pi.pdf